Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EEA and 80,000+ other tickers.
See exactly how EEA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EEA and 80,000+ other tickers.
The European Equity Fund, Inc. (EEA) is a closed-end investment fund primarily focused on European public equities. Established by Deutsche Investment Management Americas Inc., its portfolio management is overseen by Deutsche Asset Management International GmbH. The fund strategically allocates capital across diversified sectors within the European market, investing predominantly in shares and equity-linked instruments of various companies. It benchmarks its performance against the MSCI-EMU Index. Formed on July 23, 1986, and domiciled in the United States, the fund was previously known as Germany Fund Inc.
NEW YORK--(BUSINESS WIRE)--The European Equity Fund, Inc. (NYSE: EEA) (the “Fund”) announced today the results of its Annual Meeting of Stockholders held on June 30, 2026. Both of the two Class III Directors nominated by the Board of Directors, Mr. Bernhard Koepp and Dr. Wolfgang Leoni, were elected to serve a term of one year and until his respective successor is elected and qualifies. Stockholders also ratified the appointment of Ernst & Young LLP as the independent auditors for the Fund.
BitGo Singapore Pte. Ltd. (âBitGo Singaporeâ), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (âBitGoâ), the digital asset infrastructure company, a
XPENG Reports Q1 2026 Results: Gross Margin Sustains High Level of 20.6%, Accelerating Physical AI Mass Production, Commercialization and Globa
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir